Trial 9L-18-15

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Not Asked
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Casey O'Connell, M.D.
Other Trial Staff: Simbiso Peresuh, Coordinator, Suraj Chandwani, D.M., Madelyn Lefler, Coordinator, Christine Duran, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.